Direct comparison
Clinical Trial Monitoring Types Compared
On-site, remote, centralized, and risk-based monitoring compared: what each checks, when sponsors use it, and what ICH E6(R2) recommends.
Ask about Clinical Trial Monitoring Types Compared
Answers are drawn from this comparison and the rest of the CASRAI corpus, with a link to every source.
Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this
How do On-Site Monitoring, Remote Monitoring, Centralized Monitoring, Risk-Based Monitoring (RBM) compare side by side?
The table below compares On-Site Monitoring, Remote Monitoring, Centralized Monitoring, Risk-Based Monitoring (RBM) across 9 procurement-relevant dimensions, from what it is through relationship to the others.
Side-by-side comparison
| Dimension | On-Site Monitoring | Remote Monitoring | Centralized Monitoring | Risk-Based Monitoring (RBM) |
|---|---|---|---|---|
| What it is | In-person visit by a sponsor/CRA to a trial site (SIV, recurring IMVs, COV) | Same site-specific checklist as on-site, performed off-site via secure remote access to records | Remote, systematic review of accumulating data aggregated across ALL sites | The overarching strategy that decides which technique(s) apply where, how often, and how deeply |
| Where the review happens | At the investigator site, in person | Off-site, but still one site’s records reviewed individually | Centrally, across the whole trial at once | Not a location — a plan that allocates the other three |
| What's checked | Informed consent docs, SDV against source, IP accountability, essential-document currency, AE/SAE reporting (ICH E6(R2) 5.18.4) | Same items as on-site, reviewed via remote access to scanned/electronic source records | Enrollment/dropout rates, deviation frequency, AE patterns, lab outliers, query timeliness — vs. KRIs/QTLs | Whatever the trial's documented monitoring plan specifies, informed by pre-identified critical data/processes |
| Regulatory basis | ICH E6(R2) Section 5.18 (monitoring purpose and activities) | Not a separately defined ICH E6(R2) visit type — an off-site way of performing Section 5.18 activities | ICH E6(R2) Section 5.18.3 (defines the term); Section 5.0.4 (QTLs) | ICH E6(R2) Section 5.0 (Quality Management) and 5.18.3, which permit an on-site-only, combined, or justified centralized-only approach |
| Grew out of / popularized by | The traditional default monitoring model predating RBM guidance | Practical necessity during COVID-19-era travel restrictions; persisted post-pandemic where feasible | FDA's August 2013 RBM guidance and TransCelerate BioPharma's June 2013 methodology paper | Same FDA 2013 guidance and TransCelerate paper, formalized into ICH E6(R2) with the 2016 addendum |
| Typical scheduling | Historically fixed-interval; under RBM, risk-adjusted (e.g. every 4–8 weeks depending on site risk) | Substitutes for or supplements on-site IMVs at a similar risk-adjusted cadence | Continuous / ongoing (e.g. weekly dashboard review), not episodic visits | Sets the cadence and depth for the other three per a documented, risk-adjusted plan |
| Main strength | Direct, first-hand view of site conditions, facilities, and informal practices no remote technique fully replaces | Keeps site-specific, document-level review going without travel time/cost | Surfaces cross-site patterns a single site visit can't see; directs limited on-site effort to where risk actually is | Allocates finite monitoring resources to where they most reduce risk, instead of spreading them evenly regardless of need |
| Main limitation | Resource- and travel-intensive; fixed-interval on-site-only visiting does not scale efficiently to risk | Depends on a site's technical ability and local privacy/regulatory rules permitting secure remote record access | Can't verify document-level accuracy or observe physical site conditions directly; only as good as the data flowing into it | Requires upfront investment in defining KRIs/QTLs and a documented, defensible risk rationale |
| Relationship to the others | The baseline technique that centralized monitoring and RBM reallocate rather than eliminate | A delivery-mechanism variant of on-site-style review — distinct from centralized monitoring’s aggregate, cross-site scope | One specific technique within RBM — a component of it, not synonymous with it | The umbrella strategy; on-site, remote, and centralized monitoring are the tools it blends per a documented plan |
Common questions
Common questions about On-Site Monitoring vs Remote Monitoring vs Centralized Monitoring vs Risk-Based Monitoring (RBM)
Does ICH E6(R2) require risk-based monitoring?
+
ICH E6(R2) doesn't mandate one single technique for every trial, but it explicitly recommends developing a systematic, prioritized, risk-based approach to monitoring, and it permits a sponsor to justify and document a centralized-monitoring-only approach where trial-specific risk supports it (Section 5.18.3).
Can centralized monitoring completely replace on-site visits?
+
ICH E6(R2) allows a centralized-only approach where justified and documented, but most trials still keep at least some on-site presence — the Site Initiation Visit and Close-Out Visit in particular — because checks like investigational product storage conditions and physical document custody can't be verified remotely.
What's the actual difference between remote monitoring and centralized monitoring?
+
Remote monitoring is site-specific — the same document-level checklist as an on-site visit, just performed off-site. Centralized monitoring is cross-site and aggregate — pattern analysis across the whole trial’s accumulating data. They are often used together but are not the same technique.
Who decides which monitoring approach a trial uses?
+
The sponsor, or a CRO acting on the sponsor's behalf under ICH E6(R2) Section 5.2, decides and documents the approach in the trial's monitoring plan, informed by a risk assessment covering the investigational product, trial design, and site-specific risk factors.
